NCT03768063

A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B)

• Status: Active Not Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,000 (estimated)
• Sponsor: Hoffmann-La Roche · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, multicenter, extension study. Patients who are receiving clinical benefit from atezolizumab monotherapy or atezolizumab in combination with other agent(s) or combination/comparator agent(s) during participation in a Genentech or Roche-sponsored study (the parent study), who are eligible to continue treatment and who do not have access to the study treatment locally, may continue to receive study treatment in this extension study following roll-over from the parent study.

Conditions

• Cancer

Interventions

Type	Name	Description
DRUG	Atezolizumab	Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study, or switch to a fixed atezolizumab dose of 1200 mg every 3 weeks (Q3W).
DRUG	Bevacizumab	Bevacizumab will be administered as directed per the parent study.
DRUG	Alectinib	Alectinib will be administered as directed per the parent study.
DRUG	Cobimetinib	Cobimetinib will be administered as directed per the parent study.
DRUG	Vemurafenib	Vemurafenib will be administered as directed per the parent study.
DRUG	FAP IL2V	FAP IL2V will be administered as directed per the parent study.
DRUG	Venetoclax	Venetoclax will be administered as directed per the parent study.
DRUG	Enzalutamide	Enzalutamide will be administered as directed per the parent study.
DRUG	Pembrolizumab	Pembrolizumab will be administered as directed per the parent study.
DRUG	Sunitinib	Sunitinib will be administered as directed per the parent study.
DRUG	Niraparib	Niraparib will be administered as directed per the parent study.
DRUG	Cabozantinib	Cabozantinib will be administered as directed per the parent study.
DRUG	Pemetrexed	Pemetrexed will be administered as directed per the parent study.
DRUG	Paclitaxel	Paclitaxel will be administered as directed per the parent study.
DRUG	Emactuzumab	Emactuzumab will be administered as directed per the parent study.
DRUG	Rucaparib	Rucaparib will be administered as directed per the parent study.

Timeline

• Start date: 2019-02-28
• Primary completion: 2028-07-05
• Completion: 2028-07-05
• First posted: 2018-12-07
• Last updated: 2026-01-29

Locations

86 sites across 25 countries: United States, Australia, Belgium, Brazil, Bulgaria, Chile, Czechia, Denmark, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Italy, Japan, Mexico, Poland, Romania, Russia, Slovakia, South Korea, Spain, Thailand, Ukraine

Regulatory

• FDA-regulated drug study